Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
How to invest
How to easily future-proof your ASX share portfolio
How to invest
How to turn $200 a week into $1 million on the ASX
Share Fallers
Why Cochlear, Premier Investments, Siteminder, and Tamboran shares are falling
Share Fallers
Why Aeris Resources, Cochlear, Magellan, and Sunrise Energy Metals shares are fallin
ETFs
The best ASX ETFs to buy if you only want to invest once a year
Share Market News
5 things to watch on the ASX 200 on Thursday
Dividend Investing
23 ASX shares with ex-dividend dates next week
Growth Shares
Where to invest $10,000 in ASX shares in September
Healthcare Shares
Analysts reveal 3 ASX healthcare shares to sell
ETFs
How to invest $1,000 in ASX ETFs right now
Broker Notes
Should you buy ANZ, Amcor, and Cochlear shares?
Broker Notes
Does Macquarie rate Cochlear shares a buy, hold or sell after its FY25 result?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.